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Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted
110nm (in diameter) nanoparticles. The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed
here. Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials. The clinical data mainly
include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers. It is anticipated that lipoplatin will
replace cisplatin as well as increase its potential applications. For the ﬁrst time, a platinum drug has shown superiority to cisplatin,
at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering
of all of the side eﬀects of cisplatin.
1.Introduction
Over the last twenty years, the eﬀort to produce new, more
eﬀective, and less toxic cytotoxic agents has been intensive,
in order to ameliorate the treatment of cancer patients.
One of the most eﬀective agents since the late 1970s has
been cisplatin (CDDP) in patients with testicular cancer
[1], ovarian cancer [2] ,h e a da n dn e c k[ 3], and lung cancer
[4]a sw e l la sb l a d d e rc a n c e r[ 5] and in other malignancies
[6, 7]. Cisplatin was established as being quite eﬀective and
as one of the most important cytotoxic agents. It has mainly
been administered in combination with other agents. The
toxicity rendered by cisplatin has been its main drawback,
particularly nephrotoxicity [8–10]. After 1990, new agents
that did not cause nephrotoxicity were produced as a substi-
tute for cisplatin. Agents such as carboplatin [11] paclitaxel,
docetaxel, gemcitabine, vinorelbine, and irinotecan [12–
15] were used either in combination or as substitutes for
cisplatin [16, 17]. These agents succeeded in producing
no nephrotoxicity but did produce other toxicities such as
myelotoxicity, in comparison to cisplatin. The main example
was carboplatin, an analogue of cisplatin, which showed
no renal toxicity but produced higher myelotoxicity than
cisplatin. Carboplatin has often been used as a substitute for
CDDP [11, 12]i nl u n g[ 15], head and neck, and ovarian
cancers [11]. The eﬀectiveness of carboplatin was more or
less equal to that of CDDP but not better. For instance,
CDDP was shown to be more eﬀective than carboplatin in
the most common lung cancer, adenocarcinoma [18]. The
other agents, previously mentioned, are mainly administered
in combination with CDDP than as a substitute for it. Over
all of the last twenty years, cisplatin has been in regular
usage since most oncologists still believe it has priority with
regard to eﬀectiveness. Liposomal agents comprise another
direction which research is taking and several of these have
become part of clinical practice as is the case of liposomal
anthracycline. None of these agents has managed to become
a substitute for cisplatin, and they are used as second-line
treatment.
Our review article is related to a new formulation
of cisplatin, that is, liposomal cisplatin (lipoplatin). The
purposeofthisagentistobecomeasubstitutefortheoriginal
cisplatin, and, thus, the two drugs must be compared with
regard to toxicity and eﬀectiveness.
There are preclinical data in cancer cell cultures and in
animals as well as clinical data which involve Phase I studies,
pharmacokinetics and Phase II and Phase III studies. The
data in 16 published studies are related to patients with
pancreaticcancer,non-small-celllungcancer(NSCLC),head
and neck, and breast cancers.2 Journal of Drug Delivery
2. Lipoplatin: Formulation, Mechanisms,
andTechnology
Cisplatin was formulated into liposomes as depicted in
Figure 1. The lipids of lipoplatin are composed of soy
phosphatidylcholine(SPC-3),cholesterol,dipalmitoylphos-
phatidyl glycerol (DPPG), and methoxy-polyethylene glycol-
distearoyl phosphatidylethanolamine (mPEG 2000-DSPE).
The formulation was achieved by the formation of reverse
micelles between cisplatin and DPPG under special condi-
tions of pH, ethanol, ionic strength, and other parameters,
and the cisplatin-DPPG reverse micelles were subsequently
converted into liposomes by interaction with neutral lipids.
About 15 extrusions are performed to give to the nanoparti-
cles their ﬁnal size of 110nm, using a thermobarrel, extruder
andmembranesof0.2,0.1,0.08and0.05µmporesizesunder
ultra pure nitrogen pressure.
Thenanoparticles,110nmindiameter,havetheabilityto
target tumors and metastasis following intravenous admin-
istration using the compromised endothelium of the tumor
vasculature sprouted during neoangiogenesis; this process,
knownasextravasation,takesadvantageofthecompromised
endothelium of the vasculature of the tumors generated
during neoangiogenesis. Lipoplatin has shown an amazing
concentration in tumors and metastases at levels up to
200-fold higher compared to the adjacent normal tissue in
surgical specimens from patients [19].
3.MolecularMechanismsof
Cisplatinand Lipoplatin
After infusion, cisplatin is rapidly excreted in the urine
causing renal tubular damage. When it reaches normal and
malignant cells, it uses the major copper inﬂux transporter
Ctr1 for entry inside the cytoplasm (Figure 2). Ctr1 has
been convincingly demonstrated to transport cisplatin and
its analogues, carboplatin, and oxaliplatin. Two copper eﬄux
transporters, ATP7A and ATP7B, regulate the eﬄux of
cisplatin [21].
The S-containing tripeptide glutathione is present in
cells at mM concentrations, and the formation of complexes
with cisplatin plays an important role in its detoxiﬁcation
and biological activities. The depletion of glutathione levels
has been shown to increase the toxicity of cisplatin to
kidney cells. Cancer cells that are resistant to cisplatin often
have elevated glutathione levels. Glutathione could quench
DNA-Pt monofunctional adducts before they can rearrange
toxic bifunctional adducts on DNA. Human glutathione S-
transferase P1 (GSTP1) contributes to chemoresistance and
its suppression, decreasing the cisplatin-induced activation
of ERK1/2 and might have synergistic therapeutic eﬀects
[22].
Cisplatin and other apoptotic stimuli trigger the release
of cytochrome c from the mitochondrial intermembrane
space to the cytosol, which induces the formation of the
apoptosome and the activation of procaspase-9, leading to
apoptosis. The apoptosome is an Apaf-1 cytochrome c com-
plex that activates procaspase-9. Cisplatin can also activate
the proapoptotic protein Bax, resulting in cytochrome c
release, caspase activation, and apoptosis; Bax activation
is implicated in the nephrotoxicity of cisplatin [23]. Bcl-
2 plays an important role in the mitochondrial apoptotic
pathway. Although the general role of Bcl-2 is antiapoptotic,
Bcl-2 fragments resulting by caspase cleavage after cisplatin
treatment of cells in culture could promote the apoptotic
process [24]. Lipoplatin, releasing cisplatin molecules in the
cytoplasm of the tumor cell, is also proposed to activate the
mitochondrial apoptotic cascade.
Duringsignaltransduction,acellsensesboththeexternal
and internal environment and converts a stimulus into an
ordered sequence of phosphorylation-dephosphorylation,
protease degradation, gene regulation, or ion ﬂux events,
across the cell membrane. Receptor tyrosine kinases con-
tribute to chemoresistance in tumors. A number of addi-
tional properties of cisplatin are now emerging including
the activation of signal transduction pathways leading to
apoptosis. The ﬁring of such pathways may originate at the
level of the cell membrane after damage of the receptor or
lipid molecules by cisplatin, in the cytoplasm by modulation
of proteins via the interaction of their thiol groups with cis-
platin, (kinases, and other regulatory proteins and enzymes),
or ﬁnally from DNA damage via the activation of the DNA
repair pathways [25, 26].
Cisplatininductionofsignalingiscelltype,timeanddose
dependent. It induces oxidative stress and is an activator of
stress-signaling pathways especially of the mitogen-activated
protein (MAP) kinase cascades. The extracellular signal-
regulated kinase (ERK) pathway is indeed activated by cis-
platin. The acquisition of cisplatin resistance by ovarian car-
cinomacellswasassociatedwiththelossofERKactivationin
response to cisplatin [27]. ERK activation and DNA-damage
induced apoptosis are tightly linked; p53 may act as one of
the upstream regulators of ERK activation for the induction
of apoptosis in carboplatin-treated cervical cancer cells [28].
The treatment of cells with high cisplatin concentrations
(one order of magnitude higher than the IC50) induces cel-
lular superoxide formation and caspase activation indepen-
dentlyofnuclearDNAdamage.Incontrast,cisplatinconcen-
trations at IC50 doses, which do not induce acute apoptosis,
are suﬃcient for the induction of DNA damage signaling
[29].
The PI3K/Akt cascade has an important role in the
resistance of ovarian cancer cells to cisplatin, and the
inhibitionofPI3K/Aktincreasestheeﬃcacyofcisplatin[30].
The Akt-speciﬁc inhibitor LY294005 increased the eﬃcacy of
docetaxel, did not aﬀect the eﬃcacy of 6-thioguanine, and
decreased the eﬃcacy of cisplatin, lipoplatin, oxaliplatin, and
lipoxal in human colorectal adenocarcinoma sublines, sug-
gestinganovelpropertyofAktinaggravatingdrugsensitivity
[31].
Cisplatin appears to exhibit synergistic eﬀects with other
potent inducers of apoptosis such as a synthetic isothio-
cyanate; the sequential administration of both agents led to
increased intracellular platinum accumulation, glutathione
depletion, poly (ADP-ribosyl) polymerase cleavage, stimu-
lation of caspase-3 activity, upregulation of p53, FasL and
Gadd45alpha, cyclin B1 downregulation, and an increaseJournal of Drug Delivery 3
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Figure 1: Depiction of a lipoplatin nanoparticle (b). Cisplatin molecules are depicted as blue spheres surrounded by the lipid bilayer with
the PEGylated lipid sticking out like hair from the outer surface. Thus, this toxic substance, cisplatin, is camouﬂaged by its lipid shell as a
nutrient. This nanoparticle can pass undetected by macrophages after intravenous injection to human cancer patients because of its PEG
coating thus escaping immune surveillance [20]. c  CNRS Phototh` eque/SAGASCIENCE/CAILLAUD Franc ¸ois.
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Figure 2: Penetration of lipoplatin nanoparticles through the cell membrane of tumor cells. lipoplatin nanoparticles once inside the tumor
cellmasscanfusewiththecellmembranebecauseofthepresenceofthefusogeniclipidDPPGintheirlipidbilayer;analternativemechanism
proposed is that lipoplatin is taken by endocytosis by tumor cells as shown from lipoplatin containing ﬂuorescent lipids and imaging of the
tumor cells in culture thus treated with ﬂuorescent microscopy (see Figure 3). These processes occurring at the cell membrane level are
promoted by the lipid shell of the nanoparticles (disguised as nutrients) [20].4 Journal of Drug Delivery
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Figure 3: Lipoplatin or DPPG-liposomes with ﬂuorescent lipids enter rapidly MCF-7 breast cancer cells in culture. Time-course processing
of FITC-labeled DPPG-containing liposomes (a) and Lipoplatin (b) using confocal microscopy. At 5min, the majority of the signal is
localized in the membrane. Lipids are rapidly internalized and at 4–24 hours, a strong signal is observed in the cytoplasm and at the
perinuclear area. These results demonstrate that lipoplatin or DPPG-liposomes nanoparticles are able to cross the cell membrane barrier
[20].
in mitogen-activated protein kinases JNK, ERK, and p38
p h o s p h o r y l a t i o na sw e l la sP I 3 Kl e v e la l t e r a t i o n s[ 32].
4. Resistance of Tumor Cells to Cisplatin
and a Role for Lipoplatin
The resistance of tumor cells to cisplatin is attributed to at
least four diﬀerent mechanisms: (i) decreased levels of cis-
platin entrance to the cytoplasm or increased eﬄux through
the cell membrane, (ii) increased levels of glutathione, (iii)
modulation of signaling pathways, and (iv) enhanced levels
of DNA repair.
However, additional pathways have been found for
establishing the cisplatin resistant phenotype. For example,
the selection of ovarian carcinoma cells in culture in the
presence of cisplatin led to upregulated expression of the L1
adhesionmolecule;thiscouldconstituteamechanismforthe
establishment of chemoresistance and of a more malignant
tumor phenotype [33].
The direct fusion of lipoplatin nanoparticles with the
membrane of the tumor cell (Figure 2) suggests that
lipoplatin can have applications after the failure of cisplatin
front-line chemotherapy and the development of cisplatin
resistance at the cell membrane level.
5.PreclinicalStudies
A comparison of the cytotoxicity of lipoplatin and cisplatin
in vitro in established cell lines (derived from NSCLC,
renal cell carcinoma, and in normal hematopoietic cell
precursors),aswellastheidentiﬁcationofbiologicalmarkers
associated with sensitivity and resistance has rendered some
interesting data. ERCC1 and LRP expression levels appeared
to be valid predictors of sensitivity or resistance to both
drugs. A superior cytotoxicity in all tumor cell models and a
much lower toxicity in normal cells for lipoplatin compared
with cisplatin were found, suggesting a higher therapeutic
index for the liposomal compound [34].
Fedier et al. [35] investigated whether the cytotoxic eﬀect
oflipoplatin isdependentonthefunctionalintegrity ofDNA
mismatch repair (MMR). MMR is a postreplicative DNA
repair mechanism implicated in cell cycle control and apop-
tosis. MMR function was found to be a relevant determinant
accounting for the cytotoxicity of lipoplatin [35]. A possible
relationship between MMR-mediated cisplatin DNA damage
signaling, and the Akt signaling pathway was also found
[31].
The fusion between liposomes and the cell mem-
brane was suggested based on the fusogenic properties of
DPPG and lipids integrated into the shell of lipoplatin
(Figure 2). Subsequent cell culture studies where the lipids
of the lipoplatin nanoparticle were labelled with ﬂuorescein
isothiocyanate (FITC) established the rapid uptake and
internalization of the nanoparticles (Figure 3). In these
studies the ﬂuorescent nanoparticles were incubated with
MCF-7 breast cancer cells in culture for various times
ranging from 5min to 24h, and the cells were ﬁxed and
visualized by confocal microscopy (Figure 3). Liposomes
containing DPPG without cisplatin were also used as a
control. The study has provided proof that the lipids of
lipoplatin labelled with FITC are transferred initially (in
less than 5min) to the cell membrane of MCF-7 cells in
culture and are then (from 5min to 24h) docked to the
interior of the cell. The membrane fusion is proposed to
modulate signalling, an important process for cancer cell
proliferation.
The lower nephrotoxicity of lipoplatin, compared to
cisplatin, was shown in mice, rats, and SCID mice [36],
whereas animals injected with cisplatin developed renal
insuﬃciency with clear evidence of tubular damage, but
those injected with the same dose of lipoplatin were almost
completely free of kidney injury [36].
In order to explain the lower toxicity of lipoplatin
compared to cisplatin, the levels of total platinum in rat
tissue after cisplatin or lipoplatin injections were determined
at diﬀerent time intervals. The maximum levels of total
platinumaftercisplatinwerefoundinthekidneyfollowedbyJournal of Drug Delivery 5
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Figure 4: Kidney and other tissue accumulation of total platinum
after cisplatin injection of rats (0–5h) [20].
the plasma, liver, lung, spleen, heart, and brain, in those
tissues examined from 5min to 5h. At later times (up to
50h), the order of the tissues with the highest levels of
platinum was the kidney, liver spleen, plasma, lung, heart,
andbrain.Asingletreatmentwith30mg/kglipoplatininrats
resulted in no toxicity, whereas 2 or 3 weekly administrations
at 30mg/kg in rats produced neutropenia but no nephrotox-
icity. However, a single injection of 5mg/kg cisplatin in rats
resulted in severe nephrotoxicity. The levels of total platinum
attained in animal kidneys after cisplatin administration
are about the same as those after lipoplatin (Figure 4);
however, at about 1h and up to 5 days, the levels of total
platinum are about 1 microgram after lipoplatin compared
to 5 micrograms after cisplatin administration (Figure 4).
After cisplatin injection, the kidneys accumulate the
highest levels of platinum among all of the animal tissues,
followed by the liver and the lung. One hour after lipoplatin
administration i.p., the kidney Pt levels drop from 13 to
3µg/g tissue. The highest Pt levels among all of the animal
tissues are in the liver and spleen after 4h i.p. administration
maintained for over 100h.
The treatment of dogs with lipoplatin led to the conclu-
sion that the drug can be safely administered to clinically
normal dogs at dosages of up to 150mg/m2 without the need
for concurrent hydration protocols. The maximum tolerated
dose (MTD) of unencapsulated cisplatin in dogs has been
established as 70mg/m2. Therefore, lipoplatin would allow
thesafeandrepeatedadministration ofdoses higherthanthe
MTD of unencapsulated cisplatin [37].
The intrapleural administration of lipoplatin in an
animal model seems to oﬀer a more eﬀective therapeutic
index while improving tolerability. Wistar rats were treated
with doses of 10mg/kg lipoplatin (intravenously) versus
10 or 20mg/kg lipoplatin (intrapleurally) corresponding to
60 and 120mg/m2, respectively, in humans. The authors
noted minor ﬁbrotic changes in the pleura of rats injected
intrapleurally, and mild kidney changes in rats injected
intravenously, as expected [38].
6.CellularUptakeandCytoplasm/DNA
Distribution of Cisplatin versusLipoplatin
The antineoplastic or radio-sensitizing activity of platinum
drugs is attributed to their binding to DNA. The time
course of accumulation of cisplatin, lipoplatin, oxaliplatin,
and lipoxal (liposomal oxaliplatin) in the human colorectal
cancer HCT116 cell line and their distribution between
the cytoplasm and DNA were measured by inductively
coupled plasma mass spectrometry. The distribution of
cytoplasm/DNA of free cisplatin and lipoplatin were similar.
However, lipoxal displayed a higher accumulation in the
cytoplasm compared to free oxaliplatin, consistent with its
proposed mechanism of fusion with the cell membrane [39].
The cytotoxicity and synergic eﬀect of platinum com-
pounds with radiation were examined in F98 glioma cells.
Lipoplatin improved the cell uptake of cisplatin by 3-fold,
and its radiosensitizing potential was enhanced by 14-fold.
Amongtheﬁveplatinumcompoundstested,carboplatinand
lipoplatin showed the best radiosensitizing eﬀect. Lipoplatin
seemed the most promising since it led to the best cellular
incorporation and reduced all the toxicities of cisplatin [40].
7.ClinicalStudies
7.1. Pharmacokinetics. In the administration of liposomal
cisplatin to humans, the target was to determine the
pharmacokinetics and adverse reactions. A Phase I study
of 27 patients with diﬀerent malignancies was performed.
The drug was infused for 8hrs every fourteen days at
escalating doses. The drug levels started at 25mg/m2 and
were increased by 25mg/m2 up to 125mg/m2. Three-5
patients were selected for each dosage. Blood was taken
at certain time intervals in order to estimate the total
platinum plasma levels. For pharmacokinetics, blood was
drawn at 0, 3, 6, 8, 12, 24 hrs and 3, 5, 7 days, into tubes
containing EDTA, and total platinum levels (i.e., free plus
proteins bound plus liposomal) were analyzed by atomic
absorption. Total platinum was also determined in the
ultraﬁltrate of less plasma. The maximum level attained in
the plasma was 5.7µg/mL at 8hrs. The levels of platinum
in the blood after lipoplatin infusion drop to normal on
the fourth day at a dose of 100mg/m2,b u ta tad o s eo f
125mg/m2 platinum can be detected in the blood for 7
days (Table 1)[ 41]. Renal function tests (blood urea, serum
creatinine, and creatinine clearance) showed no change
before and after treatment. The excretion of platinum in
the urine in lipoplatin-treated patients attains a maximum
within8hrs(infusionperiod)anddeclinesthereafter.During
the 3 following days (after infusion) 40.7% of the total
platinum was excreted in the urine. Toxicity was very mild
(grade 1 or 2 neutropenia and nausea/vomiting) at the
125mg/m2 dosage level. In another trial, the tumor uptake
of lipoplatin was examined in comparison to normal tissue,
in 4 patients with hepatocellular adenocarcinoma, gastric
cancer, and colon cancer. Lipoplatin was administered to the
patients 24 hours before the surgery [19]. This study showed
liposomal cisplatin accumulation in tumors as compared to
normal tissue after the intravenous infusion of lipoplatin.6 Journal of Drug Delivery
Table 1: Pharmacokinetic parameters of total platinum in patients’ sera at the diﬀerent dose levels.
Dose Pts AUC0∅A Cmax Cl Kel t1/2 Vss
mg/m2 (n)( h µg/mL) (µg/mL) (L/m2 h) (L/h) (h) (L/m2)
25 5 139.63 2.48 ± 1.18 0.18 0.0114 60.79 15.71
50 3 119.19 2.87 ± 0.59 0.42 0.0001 N/A N/A
100 5 172.89 3.74 ± 1.18 0.58 0.0059 117.46 98.03
125 4 256.09 5.65 ± 2.67 0.49 0.0085 81.53 57.42
N/A, not applicable.
Among the various surgical specimens examined, gastric
tumors revealed the highest levels of total platinum (up
to 262µgcisplatin/gr tissue). The liver metastatic specimen
displayed a total amount of 131.15µgplatinum/gr of tissue
compared to 20.94µgplatinum/gr of normal liver tissue.
Both specimens of gastric tumors appeared to accumulate
the highest amounts of platinum among all specimens
analyzed in this study: 262.62 and 66.38µg/gr of tissue.
The total platinum levels in the colon tumor specimens
were 11.26 and 7.69µgplatinum/gr of tissue compared to
0.06µg/gr normal colon tissue [19].
7.2. Dose-Limited Toxicity and Maximum Tolerated Doses.
The human testing of this new agent primarily required the
deﬁnition of toxicity by investigating the MTD as well as the
dose-limited toxicity (DLT). Two Phase I and I-II studies
examined these objectives. The ﬁrst trial was in patients
with advanced pancreatic cancer. The results showed that the
dosages which began to produce side eﬀects were 100mg/m2
and 125mg/m2. But these dosages did not later prove
that this was the DLT since lipoplatin was combined with
gemcitabine, the latter which may have been responsible for
the toxicity [42]. The second study deﬁned similar doses as
the DLT and MTD. This trial also used two agents, lipoplatin
and gemcitabine in pretreated patients with NSCLC. The
two drugs were repeated on day 8. The small number of
13 patients was not eﬃcacious enough to determine ample
data concerning toxicity [43]. In both these aforementioned
studies, there was also a defect in that all of the patients
had undergone chemotherapy pretreatment when they were
recruited and the eﬃcacy of lipoplatin was tested. A proper
third Phase I trial was eventually performed. The main
objective of this study was to determine the DLT and MTD
of lipoplatin tested as a single agent and in combination
with a second cytotoxic agent. The selected second agent was
paclitaxel. All of the patients had NSCLC. Adverse reactions,
mainly myelotoxicity, renal toxicity and gastrointestinal tox-
icity (nausea, vomiting, diarrhea) were determined. Sixty-six
patients were recruited and evaluated. Thirty-nine patients
comprised the group that received lipoplatin monotherapy,
and 27 patients were given lipoplatin in combination with
paclitaxel. In the ﬁrst group, the dosage of lipoplatin started
at the level of 125mg/m2 and the drug-dose escalation
increased to 350mg/m2. It was determined that 350mg/m2
was the DLT and 300mg/m2 the MDT. In the group that
received combination therapy, the escalation of paclitaxel
started at 100mg/m2 a n dw e n tu pt o1 7 5 m g / m 2 and of
lipoplatin from 100mg/m2 to 250mg/m2. The results of
the combined treatment evaluation determined the DLT as
250mg/m2 and the MTD, 200mg/m2. Nausea, vomiting,
fatigue, and neutropenia were not higher than grade 1-2,
and other adverse reactions in a small percentage of patients
reachedgrade3.Inthecombinedmodality,othersideeﬀects,
such as neurotoxicity, were observed, and this was attributed
to paclitaxel. Grade 1 nephrotoxicity was observed in a small
percentage of patients, but this was only temporary (Table 2)
[44].
Over the last ﬁve years, several Phase II and III trials
have been performed in diﬀerent institutions and countries.
Lipoplatin has been tested in the following malignancies:
pancreatic cancer, head and neck cancer, mesothelioma,
breast and gastric cancer, and NSCLC. In pancreatic cancer,
lipoplatin was administered as second-line treatment in
combination with gemcitabine. The patients had initially
undergone gemcitabine monotherapy as ﬁrst-line treatment
and were experiencing disease progression. The combination
of lipoplatin with gemcitabine rendered a response rate of
8% [42].
A trial was done concerning a combination of lipoplatin
120mg/m2 plus 5-ﬂuorouracil 400mg/m2 and leucovorin,
both cytotoxic drugs administered weekly along with radio-
therapy. The cytotoxic agents were given on day 1 and
radiotherapy (dosage 3.5Gy × 3, days 2, 3, 4) for four or ﬁve
weeks. This treatment was given to patients with advanced
gastric cancer. No serious toxicity was observed, and the
therapy was well tolerated; 18.2% patients developed grade
1 renal toxicity and nausea and 25% showed fatigue. A good
response to the combined treatment was observed [45].
It is too early to conﬁrm that lipoplatin is eﬀective in
mesothelioma. There is a case report indicating the respon-
siveness of mesothelioma to lipoplatin given in combination
with gemcitabine as second-line treatment on disease recur-
rence [46].
The testing of the toxicity and eﬀectiveness of lipo-
somal cisplatin was done in patients with squamous cell
carcinoma of the head and neck. This was a randomized
study comparing lipoplatin combined with 5-ﬂuorouracil
versus cisplatin combined with 5-ﬂuorouracil. The toxicity
was well tolerated. Grade 3 renal toxicity was much lower
after lipoplatin administration than after cisplatin. Higher
myelotoxicity was observed in the cisplatin arm (31.7%
versus 12% in the lipoplatin arm). Mucositis and peripheral
neuropathy were also much higher in the cisplatin group.
The response rate was higher in the cisplatin arm, butJournal of Drug Delivery 7
Table 2: Toxicity: lipoplatin monotherapy.
Dosage lipoplatin
mg/m2 Toxicity
Grade
1234
nnnn
150–250
N a u s e a - v o m i t i n g ————
F a t i g u e ————
D i a r r h e a ————
N e p h r o t o x i c i t y ————
N e u t r o p e n i a ————
N e u r o t o x i c i t y————
300
Nausea-vomiting 2/4 1/4 — —
Fatigue 2/4 1/4 — —
Neutropenia 1/4 — — —
N e p h r o t o x i c i t y 1 / 4———
350
Nausea-vomiting 1/4 3/4 — —
Fatigue 1/4 3/4 — —
Neutropenia 2/4 1/4 1/4 —
Nephrotoxicity 2/4 1/4 1/4 —
stable disease was higher in the lipoplatin arm. This low
responsiveness of the lipoplatin arm may be due to the
quite low dosage administered and its short duration. One
shouldtakeintoaccountthattheMTDis200mg/m2 andnot
100mg/m2 [47].
A Phase II trial combining lipoplatin with vinorelbine in
ﬁrst-line treatment of HER2/neu-negative metastatic breast
cancer was done. The investigators administered the above
agents on the basis of the rationale that the frequent use
of anthracyclines and taxanes in the adjuvant setting of
breast cancer has led to drug resistance and cardiac toxicity.
This raised the need for new agents in the metastatic
setting. Another reason for testing the aforementioned com-
bination was that the use of cisplatin-vinorelbine showed
interesting results with an overall response rate of 64%.
The administered dose of lipoplatin was 120mg/m2 and of
vinorelbine 30mg/m2. The objective response rate of the
latter combination was 50% (one complete response). Stable
disease was 45.5%. Toxicity was well tolerated [48].
One Phase II and two Phase III trials have been recently
integrated and published. In these studies, lipoplatin was
combined with a second agent in comparison with cisplatin
alsocombinedwiththesamesecondagent,andtheobjectives
were to determine the side eﬀects and eﬃcacy. In the Phase
II randomized study, lipoplatin (dosage 120mg/m2 given on
days1,8,15)combinedwithgemcitabine(1000mg/m2 given
on days 1, 8) was compared with cisplatin (100mg/m2 day
1) combined with gemcitabine (1000mg/m2 g i v e no nd a y s
1, 8). With respect to eﬃcacy, the overall response rate of
the lipoplatin arm was 31.7%, and the cisplatin arm 25.6%.
Althoughtheeﬃcacyoflipoplatinwasnotstatisticallyhigher
than that of cisplatin, a better response rate was achieved
with lipoplatin, particularly in cases of adenocarcinoma. The
more important ﬁnding was the toxicity outcome which
was shown to be much lower in patients treated with
lipoplatin versus in patients treated with cisplatin. Very low
nephrotoxicity was observed in the patients who received
lipoplatin.Althoughtheaforementionedstudy[49]included
a rather limited number of patients (88 in total), the results
were conﬁrmed by another study which was done in parallel
to the above trial.
These results with respect to the study done in parallel,
mentioned above, are as follows: this Phase III trial included
229 evaluable patients. The diﬀerences between this study
and the previous one were, the number of patients, the
dosage of the drugs, the repetition of the courses, and
the second agent which was combined with lipoplatin and
cisplatin. The dose of lipoplatin was 200mg/m2,w h i c h
is the proper MTD combined with paclitaxel 135mg/m2
repeated every 2 weeks for a planned 9 courses. The
control arm received cisplatin 75mg/m2 also combined with
paclitaxel 135mg/m2, repeated every 2 weeks. The planned
number of courses was 9. The treatment of both agents
and arms was on day 1. The main objectives of this trial
were to determine the toxicity and median survival. The
results were quite impressive; nephrotoxicity, in particular,
leukopenia, nausea/vomiting, and asthenia were statistically
signiﬁcantly lower after lipoplatin treatment (P ≤ 0.001,
0.017, 0.042, 0.019, resp.) (Table 3). The comparison of
eﬃcacy was also important; the response rate was 59.7%
for the lipoplatin arm, and 47% for the cisplatin arm (no
statistically signiﬁcant diﬀerence, P = 0.073) (Table 4). The
median andoverallsurvivalforbotharmswasthesame[50].
The data documented in the last two trials indicate that
the cisplatin formulation (lipoplatin) could be considered
as the best substitute for cisplatin, at least in NSCLC, with
regard to eﬃcacy and toxicity.
The next Phase III trial was based on certain indications
from the previous trials, and this was the possibility that
NSCLC subtypes may have a diﬀerent response rate with the8 Journal of Drug Delivery
Table 3: Toxicity/statistical diﬀerences.
Toxicity grade 1–4 Arm A Arm B
n (%) n (%) P value∗
Anemia 50 (43.9) 62 (54.9) 0.112
Leucopenia (neutropenia) 38 (33.3) 52 (45.2) 0.017
Thrombocytopenia 2 (1.8) 3 (2.6) 1.000†
Nephrotoxicity (renal) 7 (6.1) 46 (40.0) <0.001
Neurotoxicity 52 (45.6) 63 (54.8) 0.145
GI toxic nausea/vomiting 37 (32.5) 52 (45.2) 0.042
GI diarrhea 2 (1.8) 3 (2.6) 1.000†
Asthenia 65 (57.0) 82 (71.3) 0.019
Alopecia 96 (84.2) 87 (75.7) 0.134
GI, gastrointestinal.
∗Pearson’s chi-square test.
†Fisher’s exact test.
Table 4: Response rate/survival time (months), Log-rank test P value: 0.577.
ARM
Response rate A B Total P value∗
CR
n 101 —
% within ARM 0.9 0.0 0.4 —
PR
n 67 54 121
% within ARM 58.8 47.0 52.8 0.073
SD
n 42 50 92
% within ARM 36.8 43.5 40.2 0.306
PD
n 41 1 1 5
% within ARM 3.5 9.6 6.6 0.064
Total n 114 115 229
Survival time n Median 95% CI
Arm A 114 9.0 6.2–11.8
Arm B 115 10.0 6.8–13.2
Total sample 229 10.0 8.3–11.7
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.
∗Pearson’s chi-square test.
Table 5: Response rate.
Arm A Arm B P value
(n = 103) (n = 99)
Partial response 61 (59.22%) 42 (42.42%) 0.036
Stable disease 35 (33.98%) 43 (43.43%) 0.220
Progressive disease 7 (6.80%) 14 (14.14%) 0.110
administrationoflipoplatinorcisplatin.Thisstudyrecruited
patients with nonsquamous cell lung cancer, mainly adeno-
carcinomas, and they were treated with lipoplatin combined
withpaclitaxelversuscisplatincombinedwithpaclitaxel.The
dosageandadministrationofthesetwocombinedtreatments
was the same as in the previous study. It was found in 202
patients randomized into two groups, that the response rate
was superior in the lipoplatin group. The diﬀerence was
statistically signiﬁcant (P = 0.036) (Table 5). The median
survival for the lipoplatin group was 10 months and forJournal of Drug Delivery 9
cisplatingroup8months,approachingstatisticalsigniﬁcance
(P = 0.1551) [51].
There are data examining the possibility of using
lipoplatin in cancer patients with renal failure. The prelim-
inary data show that patients with serum creatinine ranging
from 1.6–3.5mg/dL tolerate lipoplatin without increasing
renal failure and without side eﬀects such as neutropenia,
nausea/vomiting, and fatigue.
8. Conclusion
The eﬀorts over the last 20 years to produce a substitute for
cisplatin, a very important and eﬀective anticancer agent,
with a similarly eﬀective and less toxic agent, have not prop-
erly succeeded. The current data in a number of preclinical
and clinical trials shed new light on the previous eﬀorts
to produce a substitute for cisplatin. Liposomal cisplatin
(lipoplatin), is a new formulation of cisplatin and one would
expect at least to achieve equal eﬀectiveness. Phase I, II, and
III trials have shown lipoplatin to produce similar eﬃcacy to
that of cisplatin in pancreatic, head and neck, breast cancers,
and NSCLC (the latter has been more broadly tested). In
a new substitute for cisplatin, what is more important,
apartfromeﬀectiveness,issigniﬁcant toxicity reduction.The
reduction of toxicity, mainly nephrotoxicity, has been shown
and conﬁrmed in published trials. It will be important to use
this new cisplatin formulation in future trials and to test it in
malignancies such as ovarian and bladder cancers.
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